ADVERTISEMENT

Orchid Pharma Q4 Results Review - Foray Into Branded Formulations: Systematix

Enmetazobactam launch in Europe and U.S. is expected from Q2 FY25.

<div class="paragraphs"><p>Colorful pills. (Source: freepik)</p></div>
Colorful pills. (Source: freepik)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit